Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.66 |
| ▸ | CNR1 | P21554 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585606 | 0.88 | CNR2 (0.69) | CNR2CNR1KCNH2 | |
| SCHEMBL584520 | 0.88 | CNR2 (0.69) | CNR2CNR1KCNH2 | |
| SCHEMBL3916373 | 0.88 | CNR2 (0.69) | CNR2CNR1KCNH2 | |
| SCHEMBL5181637 | 0.88 | CNR2 (0.69) | CNR2CNR1KCNH2 | |
| SCHEMBL584412 | 0.88 | CNR2 (0.72) | CNR2CNR1KCNH2 | |
| SCHEMBL585235 | 0.85 | CNR2 (0.68) | CNR2CNR1KCNH2 | |
| SCHEMBL4966137 | 0.85 | CNR2 (0.68) | CNR2CNR1KCNH2 | |
| SCHEMBL5180515 | 0.85 | CNR2 (0.66) | CNR2CNR1KCNH2 | |
| SCHEMBL5182336 | 0.84 | CNR2 (0.65) | CNR2CNR1KCNH2 | |
| SCHEMBL5181256 | 0.84 | CNR2 (0.65) | CNR2CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | claimed |
| EP-1670769-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | claimed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | claimed |
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| US-8633235-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | NEOMED INSTITUTE (CA) | 2014-01-21 | — | — | US | disclosed |
| EP-1670769-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207612-A1 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | CYP3A4, CYP2C19, H1-3 | CNR2 691/4885CNR1 689/4885KCNH2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.